ACY-241
CAS No. 1316215-12-9
ACY-241 ( Citarinostat )
产品货号. M11281 CAS No. 1316215-12-9
ACY-241, also known as Citarinostat, is a potent, selective and orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity.
纯度: >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥786 | 有现货 |
|
10MG | ¥988 | 有现货 |
|
25MG | ¥1798 | 有现货 |
|
50MG | ¥3013 | 有现货 |
|
100MG | ¥4358 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称ACY-241
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述ACY-241, also known as Citarinostat, is a potent, selective and orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity.
-
产品描述ACY-241, also known as Citarinostat, is a potent, selective and orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, ACY-241 inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibit tumor cell division and induce tumor cell apoptosis.
-
同义词Citarinostat
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC1; HDAC2; HDAC3; HDAC6; HDAC8
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1316215-12-9
-
分子量467.95
-
分子式C24H26ClN5O3
-
纯度>98%(HPLC)
-
溶解度Soluble in DMSO
-
SMILESClC1=CC=CC=C1N(C2=CC=CC=C2)C3=NC=C(C=N3)C(NCCCCCCC(NO)=O)=O
-
化学全称2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
HDAC-IN-4
A histone deacetylase (HDAC) inhibitor.
-
Trichostatin A (TSA)
Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM – HDAC8 is the only known member of the HDAC-family that is not affected by TSA.
-
Detomidine HCl
Detomidine HCl produce dose-dependent sedative and analgesic effects, mediatated by activation of α2 catecholamine receptors.